Guggenheim Capital’s Medpace MEDP Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$2.39M Sell
4,511
-4,726
-51% -$2.18M 0.02% 679
2026
Q1
$4.44M Buy
9,237
+4,974
+117% +$2.55M 0.03% 475
2025
Q4
$2.39M Buy
4,263
+1,301
+44% +$739K 0.02% 622
2025
Q3
$1.52M Sell
2,962
-1,750
-37% -$764K 0.01% 777
2025
Q2
$1.48M Sell
4,712
-211
-4% -$63.3K 0.01% 752
2025
Q1
$1.5M Sell
4,923
-312
-6% -$105K 0.01% 723
2024
Q4
$1.74M Sell
5,235
-2,414
-32% -$819K 0.01% 701
2024
Q3
$2.55M Buy
7,649
+1,189
+18% +$452K 0.02% 742
2024
Q2
$2.66M Sell
6,460
-9,412
-59% -$3.73M 0.02% 724
2024
Q1
$6.41M Buy
15,872
+8,514
+116% +$2.99M 0.05% 470
2023
Q4
$2.26M Sell
7,358
-985
-12% -$266K 0.02% 796
2023
Q3
$2.02M Sell
8,343
-1,913
-19% -$489K 0.02% 808
2023
Q2
$2.46M Buy
10,256
+478
+5% +$99.3K 0.02% 772
2023
Q1
$1.84M Sell
9,778
-4,127
-30% -$854K 0.02% 880
2022
Q4
$2.95M Sell
13,905
-2,577
-16% -$515K 0.03% 716
2022
Q3
$2.59M Sell
16,482
-285
-2% -$45.5K 0.02% 744
2022
Q2
$2.51M Sell
16,767
-896
-5% -$130K 0.02% 805
2022
Q1
$2.89M Sell
17,663
-639
-3% -$105K 0.02% 867
2021
Q4
$3.98M Sell
18,302
-4,835
-21% -$1.01M 0.02% 771
2021
Q3
$4.38M Sell
23,137
-637
-3% -$116K 0.03% 716
2021
Q2
$4.2M Sell
23,774
-2,671
-10% -$461K 0.02% 750
2021
Q1
$4.34M Sell
26,445
-1,833
-6% -$280K 0.03% 694
2020
Q4
$3.94M Buy
28,278
+16,339
+137% +$2.06M 0.02% 694
2020
Q3
$1.33M Buy
11,939
+8,078
+209% +$934K 0.01% 1083
2020
Q2
$359K Buy
+3,861
New +$329K ﹤0.01% 1544
2020
Q1
Sell
-4,268
Closed -$359K 1942
2019
Q4
$359K Buy
4,268
+128
+3% +$9.91K ﹤0.01% 1747
2019
Q3
$348K Sell
4,140
-2,146
-34% -$162K ﹤0.01% 1786
2019
Q2
$411K Buy
6,286
+128
+2% +$7.38K ﹤0.01% 1743
2019
Q1
$363K Sell
6,158
-1,921
-24% -$115K ﹤0.01% 1830
2018
Q4
$428K Sell
8,079
-17,342
-68% -$952K ﹤0.01% 1750
2018
Q3
$1.52M Buy
+25,421
New +$1.39M 0.01% 1397

Other funds holding MEDP

Guggenheim Capital's MEDP Position: Q2 2026 in Review

Guggenheim Capital reduced its Medpace (MEDP) stake by 51% in Q2 2026, selling an estimated $2.18M and leaving 4,511 shares worth $2.39M. The position accounts for 0.02% of the portfolio, ranked #679.

Guggenheim Capital first reported a position in MEDP in Q3 2018 and has held it in 31 quarters since. The position peaked at $6.41M in Q1 2024. 695 funds tracked by Wall St. Rank hold MEDP as of Q2 2026.

  • Guggenheim Capital held 4,511 shares of Medpace worth $2.39M as of Q2 2026.
  • Guggenheim Capital sold 4,726 Medpace shares in Q2 2026, an estimated $2.18M.
  • Medpace made up 0.02% of Guggenheim Capital's portfolio in Q2 2026, its #679 holding.
  • Guggenheim Capital first reported a position in Medpace in Q3 2018 and has held it in 31 quarters since.
  • Guggenheim Capital's Medpace position peaked at $6.41M in Q1 2024.
  • 695 funds tracked by Wall St. Rank held Medpace as of Q2 2026.

Based on Guggenheim Capital's 13F filing for Q2 2026, filed 12 Aug 2026.